Dyne Therapeutics Stock Alpha and Beta Analysis
| DYN Stock | USD 29.69 0.04 0.13% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Dyne Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Dyne Therapeutics over a specified time horizon. Remember, high Dyne Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Dyne Therapeutics' market risk premium analysis include:
Beta 2.52 | Alpha (0.80) | Risk 5.41 | Sharpe Ratio (0.08) | Expected Return (0.45) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Dyne |
Dyne Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Dyne Therapeutics market risk premium is the additional return an investor will receive from holding Dyne Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Dyne Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Dyne Therapeutics' performance over market.| α | -0.8 | β | 2.52 |
Dyne Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Dyne Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Dyne Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Dyne Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Dyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Dyne Therapeutics shares will generate the highest return on investment. By understating and applying Dyne Therapeutics stock market price indicators, traders can identify Dyne Therapeutics position entry and exit signals to maximize returns.
Dyne Therapeutics Return and Market Media
The median price of Dyne Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 33.31 with a coefficient of variation of 13.76. The daily time series for the period is distributed with a sample standard deviation of 4.63, arithmetic mean of 33.67, and mean deviation of 3.13. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 6204 shares by Kersten Dirk of Dyne Therapeutics at 46.01 subject to Rule 16b-3 | 08/30/2024 |
2 | Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Wants Impacted Shareholders To Reach Out | 09/18/2024 |
3 | Disposition of 23671 shares by Kersten Dirk of Dyne Therapeutics at 35.35 subject to Rule 16b-3 | 10/16/2024 |
4 | Disposition of 13414 shares by Kersten Dirk of Dyne Therapeutics at 35.16 subject to Rule 16b-3 | 10/18/2024 |
5 | Disposition of 18750 shares by Scalzo Richard William of Dyne Therapeutics at 10.72 subject to Rule 16b-3 | 10/25/2024 |
6 | Decoding Vistras Options Activity Whats the Big Picture | 10/30/2024 |
7 | The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations | 11/04/2024 |
8 | 7,183 Shares in Dyne Therapeutics, Inc. Acquired by Hanseatic Management Services Inc. | 11/07/2024 |
9 | Vistra Options Trading A Deep Dive into Market Sentiment | 11/12/2024 |
10 | FMR LLC Bolsters Position in Dyne Therapeutics Inc with Significant Share Acquisition | 11/13/2024 |
11 | Disposition of 8929 shares by Kersten Dirk of Dyne Therapeutics at 32.82 subject to Rule 16b-3 | 11/14/2024 |
12 | Dyne Therapeutics SVP sells 77,127 in stock | 11/18/2024 |
13 | Dyne Therapeutics director Incerti Carlo sells 474,045 in stock | 11/19/2024 |
14 | Dyne Therapeutics Inc. Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts | 11/22/2024 |
About Dyne Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Dyne or other stocks. Alpha measures the amount that position in Dyne Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.11 | 0.1 | Days Of Inventory On Hand | 49.86 | 48.73 |
Dyne Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Dyne Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dyne Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Dyne Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Dyne Therapeutics. Please utilize our Beneish M Score to check the likelihood of Dyne Therapeutics' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Dyne Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Dyne Therapeutics Backtesting, Dyne Therapeutics Valuation, Dyne Therapeutics Correlation, Dyne Therapeutics Hype Analysis, Dyne Therapeutics Volatility, Dyne Therapeutics History and analyze Dyne Therapeutics Performance. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Dyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.